Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minimum effective volume of ultrasound-guided costoclavicular brachial plexus block with 0.375% ropivacaine for arteriovenous fistula creation in renal failure
ChiCTR2100044031Phase 4Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Mar 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ropivacaine in kidney failure, sponsored by Nanfang Hospital, Southern Medical University. Primary endpoints: Minimum effective volume for successful block in 95% of patients (MEV95) and Minimum effective volume for successful block in 50% of patients (MEV50). Started Mar 2021; status: recruiting.
02
Drugs
ropivacaine
03
Conditions
kidney failure
Beyond the preview
Go deeper on ChiCTR2100044031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044031.